Osiris Therapeutics, Inc. Common Stock
OSIR
OSIR was delisted on the 16th of April, 2019.
68 hedge funds and large institutions have $36.2M invested in Osiris Therapeutics, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 18 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
23% more call options, than puts
Call options by funds: $311K | Put options by funds: $253K
13% less capital invested
Capital invested by funds: $41.6M → $36.2M (-$5.4M)
15% less funds holding
Funds holding: 80 → 68 (-12)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$666K |
| 2 |
Renaissance Technologies
New York
|
+$585K |
| 3 |
GC
Globeflex Capital
San Diego,
California
|
+$239K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$124K |
| 5 |
PP
PDT Partners
New York
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$446K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$415K |
| 3 |
Morgan Stanley
New York
|
-$321K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$252K |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
-$221K |
OSIR Hedge Fund Activity: Q2 2016 in Review
68 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Osiris Therapeutics, Inc. Common Stock (OSIR) for Q2 2016, worth a combined $36.2M — down 13% from $41.6M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of OSIR and 8 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 22 added.
The largest buyer was Deutsche Bank, adding an estimated $666K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $446K sold.
- 68 institutional investors held Osiris Therapeutics, Inc. Common Stock (OSIR) as of Q2 2016, down from 80 in Q1 2016.
- Funds reported $36.2M of Osiris Therapeutics, Inc. Common Stock stock for Q2 2016, down 13% quarter-over-quarter.
- 8 funds opened new Osiris Therapeutics, Inc. Common Stock positions in Q2 2016 and 18 closed out, a net change of -10 holders.
- The largest Osiris Therapeutics, Inc. Common Stock buyer in Q2 2016 was Deutsche Bank, an estimated $666K added.
- The largest Osiris Therapeutics, Inc. Common Stock seller in Q2 2016 was Two Sigma Investments, an estimated $446K sold.
Based on aggregated 13F filings for Q2 2016.